← Back to Home

Hepatitis D antibody gains further phase 3 evidence: 59% meet composite endpoint with weekly brelovitug

More than half of the patients in Mirum’s second pivotal trial already had cirrhosis, adding support for a planned U.S. approval application in 2027. However, improvements in viral load and liver enzymes remain a step short of proving a reduction in long-term liver disease risk.

By SURL BioNews

In treating chronic hepatitis D, lowering viral load and improving markers of liver inflammation are two linked hurdles that do not move entirely in step. Mirum Pharmaceuticals announced on November 10 that its investigational antibody brelovitug met the primary endpoint in AZURE-4, the second phase 3 trial supporting a U.S. approval application: 59% of patients receiving weekly treatment achieved both a virologic response and normalization of the liver enzyme ALT at week 24.

The result adds evidence for brelovitug in patients with a greater disease burden. AZURE-4 enrolled 113 treatment-naive patients, of whom 53% already had cirrhosis and approximately half had baseline HDV RNA above 1 million international units per milliliter. Patients were randomized into three groups: 300 mg by subcutaneous injection weekly, 900 mg every four weeks, or treatment beginning after a 12-week delay.

In the every-four-week dosing group, 44% reached the same composite endpoint, while the comparison figure reported by the company for the delayed-treatment group was 0%; both dosing groups achieved statistically significant differences versus the control. The result for the weekly 300 mg group was the prespecified primary endpoint. Although response rates differed between the two dosing schedules, this announcement is not yet sufficient to establish which regimen is better; the delayed-start control design also cannot directly establish an efficacy advantage over other drugs.

The meaning of the figures also depends on how “response” is defined. Virologic response rates were 95% and 96% in the weekly and every-four-week groups, respectively, but this measure includes a decline in viral load of at least two logarithmic units from baseline, a decline below the lower limit of quantification, or an undetectable level. A high response rate therefore does not mean the virus has been cleared; the proportions that actually achieved undetectable HDV RNA were 14% and 11%, respectively. ALT normalization provides another perspective, reflecting improvement in a marker associated with liver cell injury.

Brelovitug is a fully human monoclonal antibody targeting hepatitis B surface antigen, designed to neutralize and clear hepatitis B and hepatitis D virus particles. These AZURE-4 results follow AZURE-1, which was announced in September to have met its endpoint, giving the company support from a second phase 3 trial. Mirum also presented longer-term data at the annual meeting of the American Association for the Study of Liver Diseases, stating that continued treatment showed deeper viral suppression and improvements in liver stiffness; however, these follow-up findings from other studies must still be interpreted separately from this 24-week trial.

On safety, the company said no new safety signals were identified. Flu-like symptoms occurred in 17.2% and 18.5% of patients in the weekly and every-four-week groups, respectively, mostly after the first dose; injection-site reactions occurred in 1.7% and 7.4%, respectively. The information currently available comes primarily from company announcements and regulatory filings. Material distributed by news agencies also originates from the same announcement and does not constitute independent verification; full AZURE-4 results are expected to be presented at a subsequent medical meeting.

Mirum plans to submit a biologics license application to the U.S. Food and Drug Administration in the first half of 2027 and, if approved, aims to launch in the United States in the fourth quarter of the same year. The evidence at this stage supports improvements in viral and biochemical markers during treatment. It does not yet establish whether treatment can reduce liver failure, liver cancer, or death, nor does it answer how long the effects can be maintained after treatment stops. These questions, which bear more directly on patients’ long-term outcomes, await further follow-up.

References

  1. Mirum Pharmaceuticals / SEC
  2. Mirum Pharmaceuticals
  3. Business Wire via Stock Titan